These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27917324)

  • 1. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
    Jarow JP; Lemery S; Bugin K; Lowy N
    Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Expanded Access on FDA Regulatory Action and Product Labeling.
    Jarow JP; Moscicki R
    Ther Innov Regul Sci; 2017 Nov; 51(6):787-789. PubMed ID: 30079277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of FDA's Expanded Access Program for Investigational Drugs.
    Jarow JP; Lurie P; Ikenberry SC; Lemery S
    Ther Innov Regul Sci; 2017 Mar; 51(2):177-179. PubMed ID: 28553565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncology Expanded Access and FDA's Project Facilitate.
    Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R
    Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
    Bunnik EM; Aarts N
    BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Expanded Access in the United States: The Role of the Institutional Review Board.
    Folkers KM; Bateman-House A
    Ther Innov Regul Sci; 2018 May; 52(3):285-293. PubMed ID: 29723059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
    Wu J; Yang Y; Yu J; Qiao L; Zuo W; Zhang B
    Orphanet J Rare Dis; 2023 Nov; 18(1):368. PubMed ID: 38017575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017-2019.
    Poddar A; Raggio M; Concato J
    Ther Innov Regul Sci; 2024 Jan; 58(1):214-221. PubMed ID: 37926768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.
    Gould P; Salam T; Kimberly L; Bateman-House A; Fernandez Lynch H
    JAMA Netw Open; 2022 Nov; 5(11):e2239766. PubMed ID: 36318206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How the Critical Path Initiative Addresses CDER's Regulatory Science Needs: Some Illustrative Examples.
    Geanacopoulos M; Barratt R
    Ther Innov Regul Sci; 2015 Jul; 49(4):466-472. PubMed ID: 30222436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded access to investigational drugs in psychiatry: A systematic review.
    Vermeulen SF; Polak TB; Bunnik EM
    Psychiatry Res; 2023 Nov; 329():115554. PubMed ID: 37890403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-patient expanded access: A primer for pharmacists.
    Smith AJF; Redic KA
    Am J Health Syst Pharm; 2022 Nov; 79(23):2118-2127. PubMed ID: 36056791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs.
    Chapman CR; Eckman J; Bateman-House AS
    Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconciling States' "Right to Try" Legislation and FDA's Expanded Access Program: Legal Issues.
    Shapiro RS
    Ther Innov Regul Sci; 2017 Mar; 51(2):153-156. PubMed ID: 30231723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.
    Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM
    Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
    Riner A; Chan-Tack KM; Murray JS
    Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.